Biotech · Public company · San Diego, CA, US
Kura Oncology, Inc.
Ticker KURA · SEC CIK 0001422143
Track this companyFree. Adds Kura Oncology, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials2011 recruiting or active
Pipeline programs37From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline37
- Azacitidine (AZA)Phase 3 · Acute Myeloid Leukemia (AML)ClinicalTrials.gov · fetched Nov 12, 2026
- Cytarabine (Ara-C)Phase 3 · Acute Myeloid Leukemia (AML)ClinicalTrials.gov · fetched Nov 12, 2026
- DaunorubicinPhase 3 · Acute Myeloid Leukemia (AML)ClinicalTrials.gov · fetched Nov 12, 2026
- VenetoclaxPhase 3 · Acute Myeloid Leukemia (AML)ClinicalTrials.gov · fetched Nov 12, 2026
- ZiftomenibPhase 3 · Acute Myeloid Leukemia (AML)ClinicalTrials.gov · fetched Nov 12, 2026
- AlpelisibPhase 2 · HNSCCClinicalTrials.gov · fetched Nov 12, 2026
- HRAS Detection AssayPhase 2 · HRAS Gene MutationClinicalTrials.gov · fetched Nov 12, 2026
- ItraconazolePhase 2 · Advanced Malignant NeoplasmClinicalTrials.gov · fetched Nov 12, 2026
- MidazolamPhase 2 · Advanced Malignant NeoplasmClinicalTrials.gov · fetched Nov 12, 2026
- TipifarnibPhase 2 · HNSCCClinicalTrials.gov · fetched Nov 12, 2026
- TipifarnibPhase 2 · HRAS Gene MutationClinicalTrials.gov · fetched Nov 12, 2026
- TipifarnibPhase 2 · Leukemia, Myelomonocytic, ChronicClinicalTrials.gov · fetched Nov 12, 2026
- TipifarnibPhase 2 · Myelodysplastic SyndromesClinicalTrials.gov · fetched Nov 12, 2026
- TipifarnibPhase 2 · Relapsed or Refractory Peripheral T-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- TipifarnibPhase 2 · Thyroid CancerClinicalTrials.gov · fetched Nov 12, 2026
- ZiftomenibPhase 2 · Advanced Malignant NeoplasmClinicalTrials.gov · fetched Nov 12, 2026
- AdagrasibPhase 1 · Solid Tumors With HRAS AlterationsClinicalTrials.gov · fetched Nov 12, 2026
- AzacitidinePhase 1 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- CabozantinibPhase 1 · Solid Tumors With HRAS AlterationsClinicalTrials.gov · fetched Nov 12, 2026
- CytarabinePhase 1 · AMLClinicalTrials.gov · fetched Nov 12, 2026
- CytarabinePhase 1 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- DarlifarnibPhase 1 · Solid Tumors With HRAS AlterationsClinicalTrials.gov · fetched Nov 12, 2026
- DaunorubicinPhase 1 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- FludarabinePhase 1 · AMLClinicalTrials.gov · fetched Nov 12, 2026
- GilteritinibPhase 1 · AMLClinicalTrials.gov · fetched Nov 12, 2026
- Granulocyte colony-stimulating factorPhase 1 · AMLClinicalTrials.gov · fetched Nov 12, 2026
- IdarubicinPhase 1 · AMLClinicalTrials.gov · fetched Nov 12, 2026
- imatinib mesylatePhase 1 · Gastrointestinal Stromal Tumor (GIST)ClinicalTrials.gov · fetched Nov 12, 2026
- KO-947Phase 1 · Advanced Malignant NeoplasmClinicalTrials.gov · fetched Nov 12, 2026
- OsimertinibPhase 1 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- QuizartinibPhase 1 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- TipifarnibPhase 1 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- TipifarnibPhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- VenetoclaxPhase 1 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- ziftomenibPhase 1 · Gastrointestinal Stromal Tumor (GIST)ClinicalTrials.gov · fetched Nov 12, 2026
- ZiftomenibPhase 1 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- ZiftomenibPhase 1 · AMLClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials20
- Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard TherapyPHASE2 · RECRUITING · started Jan 15, 2027ClinicalTrials.gov NCT06930352 · fetched Nov 12, 2026
- Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AMLPHASE1 · RECRUITING · started Sep 2, 2026ClinicalTrials.gov NCT07355335 · fetched Nov 12, 2026
- Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLPHASE3 · RECRUITING · started Sep 26, 2025ClinicalTrials.gov NCT07007312 · fetched Nov 12, 2026
- A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)PHASE1 · RECRUITING · started Mar 27, 2025ClinicalTrials.gov NCT06655246 · fetched Nov 12, 2026
- A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid LeukemiaPHASE1 · RECRUITING · started Mar 7, 2025ClinicalTrials.gov NCT06448013 · fetched Nov 12, 2026
- A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute LeukemiasPHASE1 · RECRUITING · started Dec 27, 2024ClinicalTrials.gov NCT06397027 · fetched Nov 12, 2026
- Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid LeukemiaPHASE1 · RECRUITING · started Feb 22, 2024ClinicalTrials.gov NCT06001788 · fetched Nov 12, 2026
- TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia IIPHASE1_PHASE2 · RECRUITING · started Nov 3, 2023ClinicalTrials.gov NCT05848687 · fetched Nov 12, 2026
- KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsPHASE1 · RECRUITING · started Oct 18, 2023ClinicalTrials.gov NCT06026410 · fetched Nov 12, 2026
- A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AMLPHASE1 · RECRUITING · started Jul 18, 2023ClinicalTrials.gov NCT05735184 · fetched Nov 12, 2026
- Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung CancerPHASE1 · WITHDRAWN · started Feb 1, 2023ClinicalTrials.gov NCT05693090 · fetched Nov 12, 2026
- Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)PHASE1_PHASE2 · COMPLETED · started Dec 7, 2021ClinicalTrials.gov NCT04997902 · fetched Nov 12, 2026
- Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid MalignanciesPHASE1 · TERMINATED · started May 6, 2021ClinicalTrials.gov NCT04865159 · fetched Nov 12, 2026
- First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid LeukemiaPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Sep 12, 2019ClinicalTrials.gov NCT04067336 · fetched Nov 12, 2026
- Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to TherapyPHASE2 · COMPLETED · started Mar 15, 2019ClinicalTrials.gov NCT03719690 · fetched Nov 12, 2026
- First-in-Human Study of KO-947 in Non-Hematological MalignanciesPHASE1 · TERMINATED · started Apr 6, 2017ClinicalTrials.gov NCT03051035 · fetched Nov 12, 2026
- Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid LeukemiaPHASE2 · COMPLETED · started Jan 10, 2017ClinicalTrials.gov NCT02807272 · fetched Nov 12, 2026
- Tipifarnib in Subjects With Myelodysplastic SyndromesPHASE2 · TERMINATED · started Jun 1, 2016ClinicalTrials.gov NCT02779777 · fetched Nov 12, 2026
- Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard TherapyPHASE2 · COMPLETED · started Feb 25, 2016ClinicalTrials.gov NCT02464228 · fetched Nov 12, 2026
- Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS MutationsPHASE2 · COMPLETED · started May 13, 2015ClinicalTrials.gov NCT02383927 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 9, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 8, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 29, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 4, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 12, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 5, 2026 · fetched Nov 12, 2026